Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Stock Chart & Stats
$44.26
$0.37(1.44%)
At close: 4:00 PM EST
$44.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$13.37 - $45.46
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$1.32B
Enterprise Value$411.31M
Total Cash (Recent Filing)$402.61M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 19, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding39,816,223
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.06
Price to Sales (P/S)116.48
P/FCF Ratio-9.28
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue133.63
Enterprise Value/Gross Profit133.63
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$67.25Price Target Upside51.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPhase 3 CAPTIVATE CIDP trial is enrolling faster than expected, with interim analysis now expected earlier than initially planned.
Financial SustainabilityDianthus Therapeutics has approximately $525 million in adjusted cash, cash equivalents, and investments, which are expected to fund operations into 2028.
Product EfficacyClaseprubart recently demonstrated positive results in the Ph2 MaGic trial in gMG with significant improvement on all key endpoints.
Bears Say
Dose Selection ConcernsThere are questions on dose selection in Phase III for gMG, particularly the proposed 300 mg Q4W arm alongside the Q2W option.
Financial PerformanceFor 3Q25, Dianthus reported a net loss of $0.97 per share, which was higher than the consensus estimate of a $0.87 loss per share.
Investor SentimentShort interest for Dianthus Therapeutics' stock is relatively high at 12.3% of the float, indicating potential skepticism or bearish sentiment from investors.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $13.37 and its highest was $45.45 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $1.32B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 101 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.867 by -$0.103.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 39,816,223 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.867. Following the earnings report the stock price went up 8.005%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.25 (51.94% Upside)
$67.25 (51.94% Upside)
Hedge Fund Trend
Increased
By 251.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-28.57%
Trailing 12-Months
Asset Growth
-11.62%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$67.25
▲(51.94% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
<0.01% Insiders
14.53% Mutual Funds
52.87% Other Institutional Investors
26.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---